Drug development for Alzheimer's disease: review

被引：61

作者：

Lao, Kejing ^{[1
,2
]}

Ji, Naichun ^{[1
,2
]}

Zhang, Xiaohua ^{[1
,2
]}

Qiao, Wenwei ^{[1
,2
]}

Tang, Zhishu ^{[3
]}

Gou, Xingchun ^{[1
,2
,3
]}

机构：

[1] Xian Med Univ, Shaanxi Key Lab Brain Disorders, Xian, Shaanxi, Peoples R China

[2] Xian Med Univ, Inst Basic & Translat Med, Xian, Shaanxi, Peoples R China

[3] Shaanxi Univ Chinese Med, Inst Holist Integrated Med, Xianyang 712046, Shaanxi, Peoples R China

来源：

JOURNAL OF DRUG TARGETING | 2019年 / 27卷 / 02期

关键词：

Drug targets; receptors; neurodegenerative diseases; antagonist; drug development; AMYLOID PRECURSOR PROTEIN; AGGREGATION INHIBITOR THERAPY; GALANTAMINE PRO-DRUG; DOUBLE-BLIND; A-BETA; SAFETY; TAU; SECRETASE; PLACEBO; MILD;

D O I：

10.1080/1061186X.2018.1474361

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is considered as one of the most intractable medical problems with heavy social and economic costs. The current drugs for AD, including acetylcholinesterase inhibitors (AChEIs) and memantine, a NMDA receptor antagonist, only temporarily ameliorate cognitive decline, but are unable to stop or reverse the progression of dementia. This paper reviewed the recent advance in AD drug development. The drug discovery programs under clinical trials targeting cholinergic system, alpha 7 nicotinic acetylcholine receptors (nAChRs), N-methyl-d-aspartate receptor (NMDAR), beta-secretase, gamma-secretase modulators, tau, inflammatory mediators and glucagon-like peptide-1 (GLP-1) were discussed. Though several drug discovery programs are ongoing, the high failure rate is an outstanding issue. Novel techniques and strategies are desperately needed to significantly accelerate this process.

引用

页码：164 / 173

页数：10

共 98 条

[1] Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ [J].

Adlard, Paul A. ;

Cherny, Robert A. ;

Finkelstein, David I. ;

Gautier, Elisabeth ;

Robb, Elysia ;

Cortes, Mikhalina ;

Volitakis, Irene ;

Liu, Xiang ;

Smith, Jeffrey P. ;

Perez, Keyla ;

Laughton, Katrina ;

Li, Qiao-Xin ;

Charman, Susan A. ;

Nicolazzo, Joseph A. ;

Wilkins, Simon ;

Deleva, Karolina ;

Lynch, Toni ;

Kok, Gaik ;

Ritchie, Craig W. ;

Tanzi, Rudolph E. ;

Cappai, Roberto ;

Masters, Colin L. ;

Barnham, Kevin J. ;

Bush, Ashley I. .

NEURON, 2008, 59 (01) :43-55

[2]

Albala B., 2012, ALZHEIMERS DEMENT, V8, pS743, DOI [10.1016/j.jalz.2013.08.023, DOI 10.1016/j.jalz.2013.08.023, DOI 10.1016/J.JALZ.2013.08.023]

[3] A review on cholinesterase inhibitors for Alzheimer's disease [J].

Anand, Preet ;

Singh, Baldev .

ARCHIVES OF PHARMACAL RESEARCH, 2013, 36 (04) :375-399

[4] Solanezumab: too late in mild Alzheimer's disease? [J].

不详 .

LANCET NEUROLOGY, 2017, 16 (02) :97-97

[5]

[Anonymous], 2012, ALZHEIMERS DEMENT, DOI DOI 10.1016/J.JALZ.2012.05.237

[6]

[Anonymous], BMJ BRIT MED J

[7]

[Anonymous], ALZHEIMERS RES THER

[8]

[Anonymous], 2014, COCHRANE DATABASE SY

[9]

Arai H., 2013, Alzheimers Dementia, V9, pP282, DOI [10.1016/j.jalz.2013.05.564, DOI 10.1016/J.JALZ.2013.05.564]

[10] Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease [J].

Baddeley, Thomas C. ;

McCaffrey, Jennifer ;

Storey, John M. D. ;

Cheung, John K. S. ;

Melis, Valeria ;

Horsley, David ;

Harrington, Charles R. ;

Wischik, Claude M. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 352 (01) :110-118

← 1 2 3 4 5 6 7 8 9 10 →